Shares of Keryx Biopharmaceuticals, Inc. (KERX) Hit 52-Week Low on Second Quarter Earnings Results
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer, recently announced its financial results for the second quarter ending June 30, 2008. Shares hit a 52-week low this week after the company reported a net loss for the second quarter of $7.7 million or $0.17 per share. Total revenue improved year over year, compared to a net loss of $19.5 million or $0.45 per share, for the comparable quarter in 2007, beating consensus estimates from analysts of…